Safe harbours for the integration of new DNA in the human genome

Interactions between newly integrate DNA and the host genome limit the reliability and safety of transgene integration for therapeutic cell engineering and other applications. Although targeted gene delivery has made considerable progress, the question of where to insert foreign sequences in the human genome to maximize safety and efficacy has received little attention. In this Opinion article, we discuss 'genomic safe harbours' — chromosomal locations where therapeutic transgenes can integrate and function in a predictable manner without perturbing endogenous gene activity and promoting cancer.

[1]  M. R. Delgado Alvira,et al.  Adeno-associated viruses undergo substantial evolution in primates during natural infections , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Eric D. Adler,et al.  Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.

[3]  Frederic D. Bushman,et al.  Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. , 2010, Blood.

[4]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[5]  Michel Sadelain,et al.  Hematopoietic stem cell engineering at a crossroads. , 2012, Blood.

[6]  D. Cox,et al.  Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15 , 1984, Nature.

[7]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[8]  J. Maloof Recent advances in regulation of flowering , 2010, F1000 biology reports.

[9]  Linzhao Cheng,et al.  Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. , 2011, Blood.

[10]  E. Henckaerts,et al.  Adeno-associated virus: a key to the human genome? , 2010, Future virology.

[11]  C. Mackay,et al.  Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. , 1997, The American journal of pathology.

[12]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[13]  Frédéric Pâques,et al.  Meganucleases and DNA double-strand break-induced recombination: perspectives for gene therapy. , 2007, Current gene therapy.

[14]  Kathryn L. Parsley,et al.  Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.

[15]  Xiangdong Fang,et al.  Locus control regions. , 2002, Blood.

[16]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[17]  S. Rivella,et al.  Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. , 1998, Seminars in hematology.

[18]  Paul Shinn,et al.  Integration Targeting by Avian Sarcoma-Leukosis Virus and Human Immunodeficiency Virus in the Chicken Genome , 2005, Journal of Virology.

[19]  Manfred Schmidt,et al.  Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy , 2009, Science.

[20]  R. Pedersen,et al.  Robust, Persistent Transgene Expression in Human Embryonic Stem Cells Is Achieved with AAVS1‐Targeted Integration , 2008, Stem cells.

[21]  D. W. Emery The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. , 2011, Human gene therapy.

[22]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[23]  Lei Zhang,et al.  Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. , 2010, Genome research.

[24]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[25]  M. Jasin,et al.  Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis , 2010, Nature Reviews Molecular Cell Biology.

[26]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[27]  R. Jaenisch,et al.  Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases , 2009, Nature Biotechnology.

[28]  C. Ramachandra,et al.  Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors , 2011, Nucleic acids research.

[29]  D. Haussler,et al.  Ultraconserved Elements in the Human Genome , 2004, Science.

[30]  Mario R. Capecchi,et al.  Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century , 2005, Nature Reviews Genetics.

[31]  Zeger Debyser,et al.  LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  G. Keller,et al.  Identification and targeting of the ROSA26 locus in human embryonic stem cells , 2007, Nature Biotechnology.

[33]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[34]  Luca Biasco,et al.  Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. , 2007, The Journal of clinical investigation.

[35]  Takeshi Suzuki,et al.  Genome-Based Identification of Cancer Genes by Proviral Tagging in Mouse Retrovirus-Induced T-Cell Lymphomas , 2003, Journal of Virology.

[36]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[37]  Michel Sadelain,et al.  Occurrence of leukaemia following gene therapy of X-linked SCID , 2003, Nature Reviews Cancer.

[38]  L A Herzenberg,et al.  Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Kotin,et al.  Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination. , 1992, The EMBO journal.

[40]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[41]  A. Zander,et al.  Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. , 2003, Blood.

[42]  Luca Biasco,et al.  Comprehensive genomic access to vector integration in clinical gene therapy , 2009, Nature Medicine.

[43]  Y. Isaka,et al.  Perspectives for gene therapy in renal diseases. , 2004, Internal medicine.

[44]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.

[45]  Shoshannah L. Roth,et al.  A method to sequence and quantify DNA integration for monitoring outcome in gene therapy , 2011, Nucleic acids research.

[46]  T. Kanda,et al.  Identification of an Insulator in AAVS1, a Preferred Region for Integration of Adeno-Associated Virus DNA , 2003, Journal of Virology.

[47]  M. Jasin,et al.  Genetic manipulation of genomes with rare-cutting endonucleases. , 1996, Trends in genetics : TIG.

[48]  Philip R. Johnson,et al.  Characterization of Adeno-Associated Virus Genomes Isolated from Human Tissues , 2005, Journal of Virology.

[49]  Takeshi Suzuki,et al.  RTCGD: retroviral tagged cancer gene database , 2004, Nucleic Acids Res..

[50]  G. Karpen,et al.  Position-effect variegation and the new biology of heterochromatin. , 1994, Current opinion in genetics & development.

[51]  T. Bestor Gene silencing as a threat to the success of gene therapy. , 2000, The Journal of clinical investigation.

[52]  Thomas R Gingeras,et al.  Origin of phenotypes: genes and transcripts. , 2007, Genome research.

[53]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[54]  B. Wakimoto,et al.  Heterochromatin and gene expression in Drosophila. , 1995, Annual review of genetics.

[55]  Knut Reinert,et al.  Integration Preferences of Wildtype AAV-2 for Consensus Rep-Binding Sites at Numerous Loci in the Human Genome , 2010, PLoS pathogens.

[56]  H. Ogino,et al.  Highly efficient transgenesis in Xenopus tropicalis using I-SceI meganuclease , 2006, Mechanisms of Development.

[57]  E. Whitelaw,et al.  The vagaries of variegating transgenes. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[58]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[59]  D. Kioussis,et al.  Locus control regions: overcoming heterochromatin-induced gene inactivation in mammals. , 1997, Current opinion in genetics & development.

[60]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[61]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[62]  Michel Sadelain,et al.  Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells , 2011, Nature Biotechnology.

[63]  S. Kattman,et al.  Site-specific integration of adeno-associated virus involves partial duplication of the target locus , 2009, Proceedings of the National Academy of Sciences.

[64]  M. Sadelain,et al.  Reconstructing blood from induced pluripotent stem cells , 2010, F1000 medicine reports.

[65]  D. Persons,et al.  Solving the problem of γ-retroviral vectors containing long terminal repeats. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[67]  Christof von Kalle,et al.  and insertional genotoxicity Cell culture assays reveal the importance of retroviral vector design for , 2006 .

[68]  Frederic D Bushman,et al.  Integration target site selection by a resurrected human endogenous retrovirus. , 2009, Genes & development.

[69]  F. Campagne,et al.  Characterization of the Mouse Adeno-Associated Virus AAVS1 Ortholog , 2004, Journal of Virology.

[70]  D. McDermott,et al.  CCR5: no longer a "good for nothing" gene--chemokine control of West Nile virus infection. , 2006, Trends in immunology.

[71]  P. Gregory,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[72]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[73]  Jens Boch,et al.  TALEs of genome targeting , 2011, Nature Biotechnology.

[74]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[75]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology, an Interactive Database , 2000, Nucleic Acids Res..

[76]  H. Drew,et al.  Increased complexity of wild-type adeno-associated virus-chromosomal junctions as determined by analysis of unselected cellular genomes. , 2007, The Journal of general virology.

[77]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[78]  A. Smit Interspersed repeats and other mementos of transposable elements in mammalian genomes. , 1999, Current opinion in genetics & development.

[79]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[80]  M. Sadelain,et al.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[81]  C. von Kalle,et al.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.

[82]  Margherita Neri,et al.  Site-specific integration and tailoring of cassette design for sustainable gene transfer , 2011, Nature Methods.

[83]  J. Ellis Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[84]  P. Fraser Transcriptional control thrown for a loop. , 2006, Current opinion in genetics & development.

[85]  Frederic D Bushman,et al.  Methods for integration site distribution analyses in animal cell genomes. , 2009, Methods.

[86]  Chris Sander,et al.  CancerGenes: a gene selection resource for cancer genome projects , 2006, Nucleic Acids Res..